Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-21
2009-08-11
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S251000
Reexamination Certificate
active
07572802
ABSTRACT:
The compound having the structural formula Ior a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
REFERENCES:
patent: 5565460 (1996-10-01), Suzuki et al.
patent: 6630475 (2003-10-01), Neustadt et al.
patent: 6653315 (2003-11-01), Tulshian et al.
patent: 6897217 (2005-05-01), Neustadt et al.
patent: 2002/0099061 (2002-07-01), Neustadt et al.
patent: 2004/0138235 (2004-07-01), Grezlak et al.
patent: 2004/0220194 (2004-11-01), Neustadt et al.
patent: 2005/0222164 (2005-10-01), Neustadt et al.
patent: WO 95/01356 (1995-01-01), None
patent: WO 97/05138 (1997-02-01), None
patent: WO 98/52568 (1998-11-01), None
patent: WO 01/92264 (2001-12-01), None
patent: WO 02/055083 (2002-07-01), None
patent: WO 03/032996 (2003-04-01), None
patent: WO 2005/044245 (2005-05-01), None
patent: WO 2005/103055 (2005-11-01), None
Pinna, et al., New Therapies for the treatment of Parkinson's disease: Adenosine A2A receptor Antagonists, Life Sciences, 77, 3259-67 (2005).
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050-2057.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
Ongini et al., PubMed Abstract (Ann NY Acad. Sci. 825:30-48), Oct. 1997.
Aiba et al., Total Synthesis and Antifungal Activity of 9-Methoxystrobilurin L as the Originally Proposed 1,4-Benzodioxan Structure,Bioorg. Med. Chem.Lett., 11 (2001), 2783-2786.
Baraldi et al., Synthesis of New Pyrazolo[4,3-e]1,2,4-Triazolo[1,5-c] Pyrimidine and 1,2,3-Triazolo[4,5-e]1,2,4-Triazolo[1,5-c]Pyrimidine Displaying Potent and Selective Activity as A2aAdenosine Receptor Antagonists,Bioorganic and Med. Chem. Let. 4(21) (1994) 2539-2544.
Baraldi et al., Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives: Potent and Selective A2AAdenosine Antagonists,J. Med. Chem. 39 (1996), 1164-1171.
Baraldi et al., Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists: Influence of the Chain at the N8Pyrazole Nitrogen,J. Med. Chem., 43 (2000) 4768-4780.
Baum et al., Synthesis of Electron-Deficient Oxetanes. 3-Azidooxetane, 3-Nitrooxetane, and 3,3-Dinitrooxetane,J. Org. Chem. 48 (1983), 2953-2956.
Cornelius et al., A Convenient Synthesis of Mono- and Polyhalogenated Benzocyclanones,Synth. Commun., 24, (19) (1994), 2777-2788.
Damasio, Alzheimer's Disease and related Dementias, Cecil Textbook of Medicine, 20th Ed., vol. 2, p. 1992-1996 (1996).
Huang et al., Magnesium Bromide Promoted Barbier-Type Intramolecular Cyclization of Halo-Substituted Acetals, Ketals,and Orthoesters,Tet. Lett., 40 (1999), 8647-8650.
Kanth et al., Selective Reduction of Carboxylic Acids into Alcohols Using NaBH4and I2,J. Org. Chem., 56 (1991), 5964-5965.
Layzer et al., Degenerative Disease of the Nervous System, Cecil Textbook of Medicine, 20th Ed., vol. 2, p. 2050-2057, (1996).
Lee et al., Facile Synthesis of Oxazoles Starting from Ketones,Synth. Commun., 33, (9) (2003), 1611-1614.
Merck.com, Periodic Limb Movement Disorder and Rest Syndrome (RLS), Neurologic Disorders, Sleep and Wakefulness Disorders, (2007).
Merck Manual Fifteenth Edition, Neurologic Disorders (1987), 1420-1421.
Ongini et al., Adenosine A2AReceptors and Neuroprotection,Schering-Plough Research Institute San Raffaele Science Park Via Olgettina 58 I-20132Milan, Italy, 30-40.
Orito et al., Synthesis of 5-Iodobenzofurans and 6-Iodobenzopyrans via Direct Iodination with Mercury (II) Oxide-Iodine Reagent,Synthesis, 23 (1997), 23-25.
Pinna et al., New Therapies for the treatment of Parkinson's disease: Adenosine A2A receptor Antagonists,Life Sciences, 77, 3259-67 (2005).
Popoli et al., Blockade of Striatal Adenosine A2AReceptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Straitum,The Journal of Neuroscience, 22(5) (2002) 1967-1975.
Rao et al., Parkinson's Disease: Diagnosis and Treatment,American Family Physician, 74 (12), (2006), 2046-2054.
Roche, Bioreversible Carriers in Drug Design, AmericanPharmaceutical Association and Pergamon Press(1987).
Saletu et al., Sleep Laboratory Studies in Restless Legs Syndrome Patients as Compared with Normals and acute Effects of Ropinirole,Neuropsychobiology, 41 (4), (2000), 190-199.
T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, 14 (1987).
Trenkwalder et al., The Restless Legs Syndrome, Neurology.thelancet.com, 4 (2005) 465-475.
Ungerstedt et al., Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system,Brain Research, 24 (1970), 485-493 Abstract.
Ungerstedt et al., 6-hydroxy-dopamine induced degeneration of central monoamine neurons,Eur. J. Pharmacol., 5 (1968), 107-110 Abstract.
Varelis et al., Preparation of Optically Active (S)-2-(Benzyloxy)propanal,Aust. J. Chem., 48 (1995), 1775-1779.
Weiden, PJ, EPS Profiles: the atypical antipsychotics are not all the same,PubMed, J.. Psychiatr Pract. 13 (1), (2007),13-24 Abstract.
Yacoubi et al., Adenosine A2Areceptors and depression,Neurology, 61 (Suppl 6), (2003), S82-S87.
Yacoubi et al., Adenosine A2Areceptor antagonists are potential antidepressants: evidence based on pharmacology and A2Areceptor knockout mice,British Journal of Pharmacology, 134 (2001), 68-77.
Boyle Craig D.
Chackalamannil Samuel
Lachowicz Jean E.
Shah Unmesh
Banerjee Krishna G.
Leeser Erich A
Schering Corporation
Wilson James O
LandOfFree
7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazi... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazi..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazi... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4138711